Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
  Breaking News: FDA Approves Triumeq, New Once-Daily Combination Pill
  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

Medical News

Effect of Early Versus Deferred Antiretroviral Therapy for HIV on Survival

April 9, 2009

"The optimal time for the initiation of antiretroviral therapy for asymptomatic patients with [HIV] is uncertain," the authors wrote in introducing the current study.

The researchers conducted two parallel analyses involving a total of 17,517 asymptomatic HIV patients receiving medical care in the United States or Canada from 1996 to 2005. None had previously received antiretroviral therapy. Patients in each group were stratified according to the CD4+ count at the initiation of antiretroviral therapy (351-500 cells per cubic millimeter or more than 500 cells per cubic millimeter). In each group, the researchers compared the relative risk of death for patients who started therapy when the CD4+ count was above each of the two thresholds of interest ("early therapy group") with that of patients who deferred therapy until the CD4+ count fell below these thresholds ("deferred therapy group").

The first analysis involved 8,362 patients: 2,084 (25 percent) initiated therapy at a CD4+ count of 351-500, and 6,278 (75 percent) deferred therapy. Following adjustments for calendar year, cohort of patients, and demographic and clinical characteristics, patients in the deferred therapy group had an increase in the risk of death of 69 percent compared with the early therapy group (relative risk in the deferred therapy group, 1.69; 95 percent CI, 1.26 to 2.26; P<0.001).

Advertisement
The second analysis involved 9,155 patients: 2,220 (24 percent) initiated therapy at a CD4+ count of more than 500, and 6,935 (76 percent) deferred therapy. Among patients in the deferred therapy group, there was a 94 percent increase in the risk of death (relative risk, 1.94; 95 percent CI, 1.37 to 2.79; P<0.001).

"The early initiation of antiretroviral therapy before the CD4+ count fell below two prespecified thresholds significantly improved survival, as compared with deferred therapy," the authors concluded.

Back to other news for April 2009

Adapted from:
New England Journal of Medicine
04.01.2009; doi: 10.1056/NEJMoa0807252; Mari M. Kitahata, M.D., M.P.H., and others


  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

This article was provided by CDC National Prevention Information Network. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update.
 
See Also
HIV Medications: When to Start and What to Take -- A Guide From TheBody.com
More Research on When to Start Treatment

Tools
 

Advertisement